Introducing riskScore™: A groundbreaking breast cancer risk-prediction tool

Myriad Genetic Laboratories is excited to announce the addition of our new riskScore breast cancer risk-prediction tool to the Myriad myRisk Hereditary Cancer test, beginning on August 31st, 2017.

The riskScore precision medicine tool is clinically validated to predict a woman’s risk of developing breast cancer using clinical risk factors and genetic-markers. It provides women with their remaining lifetime and 5-year risk for developing breast cancer.

riskScore analyzes over 80 well-studied genetic markers and combined with the Tyrer-Cuzick model estimates a woman’s risk for developing breast cancer. The genetic markers were recently validated in a set of over 17,000 patients in a study presented by Hughes, et al. at the American Society of Clinical Oncology (ASCO) Annual Meeting in June. An updated analysis will be presented at the National Society of Genetic Counselors (NSGC) Annual Education Conference this coming September. Additional studies are underway, with presentations and publications planned throughout the year.

The Evolution of Myriad myRisk

When Myriad myRisk was launched in 2013, it became the first test to analyze a patient’s genetic test status and clinical/family history , and represented the next-generation of hereditary cancer testing. With the addition of riskScore, myriad myRisk now provides an even more comprehensive assessment of a patient’s risk for developing breast cancer by blending  well-defined highly and moderately penetrant hereditary cancer genes, clinical risk factors, and other genetic markers.

The Myriad myRisk report and myRisk Medical Management Tool have also been updated to provide a summary of the patient’s genetic test result, riskScore result (if applicable), and clinical history analysis in an easy-to-read banner. Based on research at the time of product launch, riskScore is only calculated from women of solely European ancestry 1,2, 3 under the age of 85 and without a personal history of breast cancer, LCIS, hyperplasia4, or a breast biopsy of unknown results. A riskScore result is not calculated if the patient is known to carry a mutation in a breast cancer risk gene.

 

For more information, you may also reach out to your local Myriad Account Executive or Regional Medical Specialist, or call 1-800-4-MYRIAD (800-469-7423) for more information. Technical specifications for Myriad myRisk Hereditary Cancer with riskScore can be found at www.myriadpro.com/documents-and-forms.

References:

1. Mavaddat N, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015 Apr 8;107(5). PubMed.
2. Michailidou K, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013 Apr;45(4): 353-61.
3. Michailidou K, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015 Apr;47(4):373-80. PubMed.
4. Tyrer J, et al. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004 23:1111-30.